in accordance with amendments to SEBI (LODR) (third amendment) Regulations, 2024 read with SEBI circular No. SEBI/HO/CFD/CFD-PoD2/ CIR/P/2024/185 dated 31.12.2024. the integrated filing of financial for the quarter and year ended on 31.03.2025 enclosed herewith.

pdf

Parmax Pharma Ltd.

30 May 2025, 08:45PM

37.93

-5.34%

Result

Parmax Pharma Ltd - 540359 - FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED ON 31/03/2025.

BSE India

The board of directors of the company has its meeting held today inter alia considered and approved financial results for the quarter and financial year ended on 31st March, 2025 along with Statement of Assets and liabilities, statement of cash flow and auditor''s report issued by the statutory auditors of the company.

pdf

Parmax Pharma Ltd.

30 May 2025, 08:37PM

37.93

-5.34%

Board Meeting

Parmax Pharma Ltd - 540359 - Board Meeting Outcome for OUTCOME OF BOARD MEETING HELD ON …

BSE India

The board of directors of Parmax Pharma Limited has its meeting held today inter alia considered and approved the Audited financial statements of the company for the quarter and year ended on 31st March, 2025 along with statement of assets and liabilities and statement of cashflow along with auditor''s report issued by B A SHAH S R MEHTA & CO, statutory auditors of the company.

pdf

Parmax Pharma Ltd.

21 May 2025

37.93

-5.34%

Board Meeting

Parmax Pharma Ltd - 540359 - Board Meeting Intimation for Meeting Of The Board Of Directors …

BSE India

Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve Meeting of the Board of Directors of Parmax Pharma Limited will be held on Friday, 30th May, 2025 at 4.00 PM inter alia to consider, approve the Audited Financial Results of the quarter and Financial year ended on 31st March, 2025

pdf

Parmax Pharma Ltd.

30 Apr 2025, 03:35PM

37.93

-5.34%

Corp. Note

Parmax Pharma Ltd - 540359 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyParmax Pharma Ltd 2CIN NO.L24231GJ1994PLC023504 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 5.02 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: BHAKTI AGHERA Designation: COMPANY SECRETARY CUM COMPLIANCE OFFICER EmailId: cs@parmaxpharma.com Name of the Chief Financial Officer: KEYUR D VORA Designation: CHIEF FINANCIAL OFFICER EmailId: keyurvora@parmaxpharma.com Date: 30/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Parmax Pharma Ltd.

21 Apr 2025

37.93

-5.34%

Company Update

Parmax Pharma Ltd - 540359 - Compliance Certificate Under Regulation 7(3) Of SEBI (LODR), 2015 For …

BSE India

In compliance with Regulation 7(3) of the SEBI (LODR), 2015, we hereby submit the compliance certificate for the year ended on 31st March, 2025 certifying that all activities in relation to both physical and electronic share transfer facilities are maintained by RTA of the Company M/S. Purva Sharegistry (India) Pvt. Ltd.

pdf

Parmax Pharma Ltd.

12 Apr 2025

37.93

-5.34%

Company Update

Parmax Pharma Ltd - 540359 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

a certificate dated 1st April, 2025 under Regulations 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 31st March, 2025 received from M/S Purva Sharegistry India Pvt. Ltd. , Registrar and Share Transfer Agent of the Company.

pdf

Is Parmax Pharma Ltd. worth buying?

4 Votes:

Buy 25.0%

Sell 25.0%

Hold 50.0%

31.06% Fall from 52W High

High volume+loss today

Parmax Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Parmax Pharma Ltd. on BSE